

## Company announcement no 18/2022

### Interim Report Q3 2022

EBITDA fixed herd prices (FHP) for Q3 2022 increased to 10,463 kEUR (Q3 2021: 7.536 kEUR), corresponding to an EBITDA margin FHP of 32.5% (Q1 2021: 28.2%). The quarterly EBITDA in Q3 2022 increased by 2.927 kEUR (compared to Q3 2021). Main factors where higher subsidy increased 1,1 mEUR and improved Lithuanian contribution from improved sales price and feed price ratio of EUR 4,3m, whereas negative factors being Harvest -0,6 mEUR and lower volume from Ostrov estimated to -1,5 mEUR (expected fully normalized in Q1 2023).

Sales prices in Q2 were 1.62 EUR/kg live weight, up from 1,18 EUR/kg (Q3 2021). Better prices have been driven by the price increase in LT, which increased by 0,49 EUR/kg compared to 2021 (or 48%).

Feed prices in Q3 2022 were 302 EUR/T (compared to 249 EUR/T Q3 2021). The price increases do not reflect market, as spot market price increases is significant higher. Idavang going forward has limited grain contract fixed on price, but have 6,7 mEUR profit for 2022/2023 harvest in the equity (hence reducing cost per T with approximate 64 EUR in Lithuania) during the next 12 months.

Subsidy increased with 1,1 mEUR due to subsidy in LT for high feed prices of 2,5 mEUR in Q3 2022 (and is not expected in the future), compared to 1,4 mEUR in Q3 2021 in LT/RU.

Cash flow EBITDA (without matif) in Lithuania is currently around 1,43-1,45 EUR (up from Q2 1,33-1,35 EUR), and utility prices is driving around than half of the increase.

The herd valuation in Q3 increased by 3,227 kEUR (compared to 30.06.2022). The increase is driven by increasing prices in EU as effect of reductions in production of pork in EU.

Net interest-bearing debt (NIBD) decreased to EUR 71.0m in Q3 2022, being EUR 8.4m lower than in Q4 2021 (78.5 mEUR), mainly due to subsidies received 5,1 mEUR and matif gain realized.

#### EURRUB exchange rate

Idavang have chosen to use the official FX rates from Central bank of Russia due to input from auditors. Q2 have been restated.

Impact of this is significant as RUB as value increase 52% since 31.12.2021.

### Selected financial highlights and key ratios

EUR millions	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Total revenue	32.172	26.703	80.351	79.769	100.163
EBITDA	13.690	2.637	22.113	17.794	14.629
EBITDA margin	42,6%	9,9%	27,5%	22,3%	14,6%
EBITDA fixed herd price	10.463	7.536	16.523	15.398	14.358
EBITDA margin fixed herd price	32,5%	28,2%	20,6%	19,3%	14,3%
Net income	9.905	-46	13.049	7.899	2.413
Free cash flow	7.363	2.640	14.998	9.903	16.033
Net interest-bearing debt	71.045	83.099	71.045	83.099	78.455

## Further information

Bondholders - Claus Baltersen, CEO phone +370 (685) 34 104

Media - Jytte Rosenmaj, Board Member phone +45 26 73 46 99

## Finance Calendar 2022

28<sup>th</sup> February 2023: Annual report 2022

## Forward-looking statements

This interim report contains “forward-looking statements.” Undue reliance should not be placed on forward-looking statements because they relate to and depend on circumstances that may or may not occur in the future, and actual results may differ materially from those in forward-looking statements. Forward-looking statements include, without limitation, statements regarding our business, financial circumstances, strategy, results of operations, financing and other plans, objectives, assumptions, expectations, prospects, beliefs and other future events and prospects. We undertake no obligation and do not intend to publicly update or revise any of these forward-looking statements unless prescribed by law or by stock exchange regulation.

## Table of contents

REVIEW .....	4
Financial Highlights and Key Ratios.....	4
Management's Review .....	5
Statement by the Board and the Executive Management.....	8
FINANCIAL STATEMENT .....	9
Income Statement .....	9
Statement of comprehensive income .....	9
Assets .....	10
Liabilities and Equity.....	11
Cash Flow Statement .....	12
Statement of changes in equity .....	13
Notes.....	14
Quarterly Financial Highlights and Key Ratios.....	19

## Review

### Financial Highlights and Key Ratios

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
<b>Income statement</b>					
Revenue	32.172	26.703	80.351	79.769	100.163
EBITDA	13.690	2.637	22.113	17.794	14.629
EBITDA fixed herd price	10.463	7.536	16.523	15.398	14.358
EBIT	11.532	786	16.506	12.340	7.497
Financial items, net	-458	-1.539	-1.080	-4.257	-5.469
Profit/(loss) for the period	9.905	-46	13.049	7.899	2.413
<b>Cash flow</b>					
Operating activity	8.005	-323	14.684	5.373	11.396
Investing activity	-3.831	1.298	-4.763	-318	-1.122
Financing activity	-2.236	-5.611	-13.342	-12.119	-11.230
Free cash flow	7.363	2.640	14.998	9.903	16.033
<b>Balance sheet</b>					
Non-current assets	113.257	94.257	113.257	94.257	93.926
Net working capital	45.715	36.684	45.715	36.684	26.866
Net operating assets	158.972	130.941	158.972	130.941	120.792
Total assets	187.100	149.962	187.100	149.962	146.166
Equity	83.839	44.658	83.839	44.658	39.744
Net interest bearing debt	71.045	83.099	71.045	83.099	78.455
<b>Key financials Group</b>					
EBITDA margin	42,6%	9,9%	27,5%	22,3%	14,6%
EBITDA margin - fixed herd prices	32,5%	28,2%	20,6%	19,3%	14,3%
Cash conversion - fixed herd prices	70%	35%	91%	64%	112%
NIBD / EBITDA fixed price LTM	4,6	5,2	4,6	5,2	5,5
Equity ratio	44,8%	29,8%	44,8%	29,8%	27,2%

## Management's Review

### Income statement

#### Revenue

The revenue for Q3 2022 was 32,172 kEUR (Q3 2021: 26,703 kEUR) up 20%. The higher sale price (37%) is the reason for increase, and also compensate for missing volume from Ostrov farm.

#### Value adjustment, biological assets

The herd valuation in Q3 increased by 3,227 kEUR (compared to 30.06.2022). The increase is driven by increasing prices in EU as effect of reductions in production of pork in EU.

#### EBITDA fixed herd prices (FHP)

EBITDA fixed herd prices (FHP) for Q3 2022 increased to 10,463 kEUR (Q3 2021: 7.536 kEUR), corresponding to an EBITDA margin FHP of 32.5% (Q1 2021: 28.2%). The quarterly EBITDA in Q3 2022 increased by 2.927 kEUR (compared to Q3 2021). Main factors where higher subsidy increased 1,1 mEUR and improved Lithuanian contribution from improved sales price and feed price ratio of EUR 4,3m, whereas negative factors being Harvest -0,6 mEUR and lower volume from Ostrov estimated to -1,5 mEUR (expected fully normalized in Q1 2023).

Sales prices in Q2 were 1.62 EUR/kg live weight, up from 1,18 EUR/kg (Q3 2021). Better prices have been driven by the price increase in LT, which increased by 0,49 EUR/kg compared to 2021 (or 48%). Feed prices in Q3 2022 were 302 EUR/T (compared to 249 EUR/T Q3 2021). The price increases do not reflect market, as spot market price increases is significant higher. Idavang going forward has limited grain contract fixed on price, but have 6,7 mEUR profit for 2022/2023 harvest in the equity (hence reducing cost per T with approximate 64 EUR in Lithuania) during the next 12 months.

#### Net financials

The net interest expenses Q3 2022 equals 392 kEUR which include 1.516 kEUR savings on repurchased bonds. Net financials excluding savings equals 1.908 kEUR is mainly bond cost, but Russia financial expenses have increased due to stronger RUB.

#### Balance Sheet

At 30<sup>th</sup> September 2022, Idavang's balance sheet amounted to 187,100 kEUR (December 2021: 146,166 kEUR). Equity on 30<sup>th</sup> September 2022 amounted to EUR 83.8m at an equity ratio of 44,8%. Net interest-bearing debt (NIBD) decreased to EUR 71.0m in Q3 2022, being EUR 8.4m lower than in Q4 2021 (78.5 mEUR), mainly due to subsidies received 5,1 mEUR and matif gain realized.

Idavang has around 3,0 years duration with the EUR 75m bond left, hence having very stable financing. The networking capital increased with 18,8 mEUR (to 45,7 mEUR 31.09.2022) compared to Q4 2021. The increase is due to price increase in commercial herd (9,2 mEUR) and currency effect from strong RUB (11,0 mEUR).

#### Cash flow

Cash flow from ordinary activities for Q3 2022 decreased to -3.831 kEUR (Q3 2021: 1.298 kEUR). The decrease of 5,129 kEUR is mainly due the insurance sum from Ostrov being included in other receivables in Q3 2021.

#### Situation in Russia

Idavang has as earlier stated isolated the activities in Russia. Hence, money is not transferred from Denmark to Russia or vice versa. All investments in Russia are stopped.

Idavang follows the situation closely to secure that the company continues to be in compliance with all Danish and EU sanctions towards Russia.

If Russia's current status in the world is not significant improved, it is estimated that it will be very difficult to operate in Russia. Results will be negative influenced due to supplies, market conditions, political factors etc

From an economic point of view the production in Russia is approximate half of the Groups activity, and a significant part of the security towards the listed bond.

#### Post Balance Sheet Events

No post balance sheet events

## Development in segments in Q3 2022

### Lithuania

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Revenue	20.213	13.728	52.705	42.180	53.864
Value adjustment, biological assets	2.720	-4.359	6.970	710	159
Production costs	-17.743	-14.820	-48.549	-42.050	-56.338
Administrative costs	-516	-425	-1.567	-1.317	-1.808
Other income	3.110	1.129	6.578	1.770	2.818
Other expense	8	11	20	333	-
<b>Operating profit</b>	<b>7.792</b>	<b>-4.736</b>	<b>16.157</b>	<b>1.627</b>	<b>-1.305</b>
Net Financials	-257	-292	-815	-897	-969
Foreign exchange adjustments	-	-	-	-	14
<b>Profit before tax</b>	<b>7.535</b>	<b>-5.028</b>	<b>15.341</b>	<b>731</b>	<b>-2.260</b>
Tax on profit for the year	-1.140	745	-2.318	-123	492
<b>Profit for the period</b>	<b>6.395</b>	<b>-4.284</b>	<b>13.023</b>	<b>608</b>	<b>-1.768</b>

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Depreciations included in production cost	-633	-714	-1.946	-2.196	-2.905
<b>EBITDA</b>	<b>8.424</b>	<b>-4.023</b>	<b>18.103</b>	<b>3.824</b>	<b>1.600</b>
<i>EBITDA fixed herd prices</i>	<i>5.704</i>	<i>337</i>	<i>11.133</i>	<i>3.113</i>	<i>1.441</i>



Lithuania accounted for 63 % of Group revenue in Q3 2022 (Q1 2023 2021: 51 %).

The EBITDA fixed herd price for Q3 2022 amounted to 5.704 kEUR, corresponding to an EBITDA margin of 28.2% (Q3 2021: 337 kEUR and EBITDA margin 2.5 %). Hence, the EBITDA fixed herd price increased compared to Q3 2021 with EUR 5,4m.

Subsidy received 2,5 mEUR (0,0 mEUR 2021) is significant part of the improvement and is not expected in the future.

The sales price in Q3 2022 increased 48 % compared to Q3 2021 to an average 1,51 EUR per kilo slaughter pigs' live weight (Q3 2021: 1,02 EUR per kilo live weight slaughter pigs) with an effect of EUR 6,4m, whereas higher feed prices impacted Q3 2022 negative (with EUR 2.1m). Cost per kg.

The remaining (negative) impact compared to Q3 2021 of 1,4 mEUR mainly is energy related.



## Russia

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Revenue	11.960	12.975	27.646	37.588	46.298
Value adjustment, biological assets	507	-540	-1.380	1.686	112
Production costs	-8.229	-6.405	-24.896	-27.433	-42.010
Administrative costs	-426	-377	-995	-963	-1.287
Other income	64	492	345	726	6.865
Other expense	-	-518	-	-518	-551
<b>Operating profit</b>	<b>3.875</b>	<b>5.627</b>	<b>721</b>	<b>11.087</b>	<b>9.428</b>
Net Financials	-349	-399	-857	-1.061	-1.203
Foreign exchange adjustments	-8	18	113	-15	-209
<b>Profit before tax</b>	<b>3.519</b>	<b>5.247</b>	<b>-23</b>	<b>10.011</b>	<b>8.016</b>
Tax on profit for the year	-29	-38	-58	-62	-107
<b>Profit for the period</b>	<b>3.490</b>	<b>5.209</b>	<b>-81</b>	<b>9.949</b>	<b>7.909</b>



EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Depreciations included in production cost	-1.526	-1.138	-3.661	-3.257	-4.227
<b>EBITDA</b>	<b>5.401</b>	<b>6.765</b>	<b>4.382</b>	<b>14.345</b>	<b>13.655</b>
<i>EBITDA fixed herd prices</i>	<i>4.894</i>	<i>7.305</i>	<i>5.762</i>	<i>12.658</i>	<i>13.544</i>

Russia accounted for 37 % of Group revenue in Q3 2022 (Q3 2021: 49 %).

The EBITDA fixed herd price for Q3 2022 amounted to 4.894 kEUR, corresponding to an EBITDA margin of 40.9% (Q3 2021: 7.305 kEUR and EBITDA margin 56.3 %). Hence, the EBITDA fixed herd price decreased compared to Q3 2021 of EUR 2,4m, mainly being Harvest -0,6 mEUR and lower volume from Ostrov estimated to -1,5 mEUR.

The sales price in Q3 2022 increased 31 % (-10% in RUB) compared to Q3 2021 to an average 1,86 EUR per kilo slaughter pigs' live weight (Q3 2021: 1,42 EUR per kilo live weight slaughter pigs) with an effect of EUR 2,8m. Whereas higher feed prices impacted Q3 2022 negative (with EUR 2.6m). Volume was lower in Q3 2022 with production volume apx. 83% of norm (due to Ostrov ASF situation), EBITDA FHP would roughly have been 1,5 mEUR higher with Ostrov in full operation.

Harvest EBITDA was 564 kEUR lower in Q3 2022 (4,072 kEUR compared to 4,636 kEUR Q3 2021). The harvest EBITDA was affected by average yields, but much lower prices in RUB (EBITDA in RUB -27%), but strong RUB reduce the negative development in EUR.



## ***Statement by the Board and the Executive Management***

The Executive Board and the Board of Directors have presented the interim Report of Idavang A/S. The interim Report has today been considered and adopted.

The Interim Report, which has not been audited or reviewed by the Company's independent auditors, was prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for listed companies.

In our opinion, the Interim Financial Statements give a true and fair view of the financial position of the Group at 30th September 2022 as well as of the results of the Group operations and cash flows for the period 1st Jan – 30th September 2022.

In our opinion, Management's Review gives a true and fair account of the development in the activities and financial circumstances of the Group, of results of operations for the period and of the overall financial position of the Group, and a description of the key risks and uncertainties facing the Group.

### **Executive Management**

Claus Baltser  
*CEO*

Michael Thuesen Henriksen  
*CFO*

### **Board of Directors**

Niels Hermansen  
*Chairman*

Jytte Rosenmaj

Carsten Lund Thomsen

Claus Baltersen

Ole B. Hansen



## Financial Statement

### Income Statement

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Revenue	32.172	26.703	80.351	79.769	100.163
Value adjustment, biological assets	3.227	-4.899	5.590	2.397	271
Production costs	-25.972	-21.225	-73.445	-69.483	-98.348
Administrative costs	-1.070	-908	-2.926	-2.646	-3.721
Other income	3.173	1.621	6.923	2.497	9.683
Other expense	1	-507	13	-192	-551
<b>Operating profit</b>	<b>11.532</b>	<b>786</b>	<b>16.506</b>	<b>12.340</b>	<b>7.497</b>
Net Financials	-392	-1.664	-2.280	-4.848	-5.991
Foreign exchange adjustments	-67	125	1.199	591	522
<b>Profit before tax</b>	<b>11.073</b>	<b>-753</b>	<b>15.425</b>	<b>8.084</b>	<b>2.028</b>
Tax on profit for the year	-1.169	707	-2.376	-185	385
<b>Profit for the period</b>	<b>9.905</b>	<b>-46</b>	<b>13.049</b>	<b>7.899</b>	<b>2.413</b>

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Depreciations included in production cost	-2.159	-1.851	-5.607	-5.454	-7.132
<b>EBITDA</b>	<b>13.690</b>	<b>2.637</b>	<b>22.113</b>	<b>17.794</b>	<b>14.629</b>
<i>EBITDA fixed herd prices</i>	<i>10.463</i>	<i>7.536</i>	<i>16.523</i>	<i>15.398</i>	<i>14.358</i>

### Statement of comprehensive income

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Profit for the period	<b>9.905</b>	<b>-46</b>	<b>13.049</b>	<b>7.899</b>	<b>2.413</b>
<b>Other comprehensive income</b>					
Exchange adjustments, foreign subsidiaries	-503	1.180	28.220	3.421	3.737
Hedge accounting	-1.537	2.460	2.826	3.471	3.726
<b>Other comprehensive income to be reclassified to profit or loss in subsequent periods</b>	<b>-2.040</b>	<b>3.640</b>	<b>31.046</b>	<b>6.892</b>	<b>7.463</b>
Other comprehensive income not to be reclassified to profit or loss in subsequent periods	-	-	-	-	-
<b>Total comprehensive income</b>	<b>7.864</b>	<b>3.594</b>	<b>44.095</b>	<b>14.791</b>	<b>9.876</b>

## Assets

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Intangible assets	1.298	1.227	1.298	1.227	1.222
Property, Plant and Equipment	98.297	79.800	98.297	79.800	79.404
Biological Assets, Breeding herd	12.456	12.023	12.456	12.023	12.094
Deferred tax	761	760	761	760	761
Financial fixed assets	445	446	445	446	446
<b>Total non-current assets</b>	<b>113.257</b>	<b>94.257</b>	<b>113.257</b>	<b>94.257</b>	<b>93.926</b>
Inventories	23.488	16.183	23.488	16.183	15.007
Biological Assets, Commercial herd	29.881	17.144	29.881	17.144	14.889
Biological Assets, Arable	1.083	634	1.083	634	1.004
<b>Biological Assets</b>	<b>30.963</b>	<b>17.779</b>	<b>30.963</b>	<b>17.779</b>	<b>15.892</b>
Trade receivables	4.077	5.036	4.077	5.036	4.404
Other receivables	1.357	8.608	1.357	8.608	494
Prepayments	1.316	665	1.316	665	2.280
Income taxes receivables	-	-	-	-	618
<b>Receivables</b>	<b>6.749</b>	<b>14.309</b>	<b>6.749</b>	<b>14.309</b>	<b>7.796</b>
Assets held for sale	-	-	-	-	-
Cash	12.642	7.434	12.642	7.434	13.545
<b>Total current assets</b>	<b>73.843</b>	<b>55.706</b>	<b>73.843</b>	<b>55.706</b>	<b>52.240</b>
<b>Total Assets</b>	<b>187.100</b>	<b>149.962</b>	<b>187.100</b>	<b>149.962</b>	<b>146.166</b>

## Liabilities and Equity

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
Share capital	800	800	800	800	800
Exchange adjustments	-6.620	-35.156	-6.620	-35.156	-34.840
Other reserves	7.099	4.017	7.099	4.017	4.273
Retained earnings	82.560	74.997	82.560	74.997	69.511
<b>Equity</b>	<b>83.839</b>	<b>44.658</b>	<b>83.839</b>	<b>44.658</b>	<b>39.744</b>
Borrowings	61.622	72.742	61.622	72.742	74.157
Grants	2.014	1.558	2.014	1.558	1.563
Deferred tax	2.074	1.625	2.074	1.625	1.029
Provisions	-	-	-	-	-
Other non-current liabilities	594	810	594	810	760
Non current liabilities	66.304	76.734	66.304	76.734	77.509
Borrowings	22.064	17.792	22.064	17.792	17.844
Trade payables	10.211	7.823	10.211	7.823	7.937
Income taxes payables	1.360	-212	1.360	-212	-
Other payables	3.322	3.167	3.322	3.167	3.132
Current liabilities	36.957	28.569	36.957	28.569	28.913
<b>Total liabilities</b>	<b>103.261</b>	<b>105.303</b>	<b>103.261</b>	<b>105.303</b>	<b>106.422</b>
<b>Total Equity and Liabilities</b>	<b>187.100</b>	<b>149.962</b>	<b>187.100</b>	<b>149.962</b>	<b>146.166</b>

## Cash Flow Statement

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2.021
Operating profit/loss	11.532	786	16.506	12.340	7.497
Adjustment for non-cash operating items	- 2.606	9.210	2.274	6.528	10.384
	8.926	9.996	18.780	18.869	17.881
Change in working capital incl. herd	1.813	- 8.240	501	- 8.568	558
<b>Cash flow from ordinary activities before financials</b>	<b>10.738</b>	<b>1.757</b>	<b>19.280</b>	<b>10.300</b>	<b>18.439</b>
Net financials	- 3.189	- 1.664	- 5.077	- 4.848	- 5.759
Corporate tax paid	455	- 415	480	- 79	- 1.284
<b>Cash flow from ordinary activities</b>	<b>8.005</b>	<b>- 323</b>	<b>14.684</b>	<b>5.373</b>	<b>11.396</b>
<b>Cash flow from investing activities</b>	<b>- 3.831</b>	<b>1.298</b>	<b>- 4.763</b>	<b>- 318</b>	<b>- 1.122</b>
Proceeds from borrowings	6.239	3.460	9.024	12.666	13.066
Repayments of borrowings	- 8.476	- 9.070	- 22.366	- 24.785	- 24.296
Dividends paid to shareholders	-	-	-	-	-
Surplus on Escrow account	-	-	-	-	-
<b>Cash flow from financing activities</b>	<b>- 2.236</b>	<b>- 5.611</b>	<b>- 13.342</b>	<b>- 12.119</b>	<b>- 11.230</b>
Cash and cash equivalents primo priod	9.978	11.777	13.545	13.757	13.757
Change in cash and cash equivalents	1.938	- 4.635	- 3.421	- 7.064	- 956
Exchange adjustments	726	292	2.518	741	744
<b>Cash and cash equivalents end priod</b>	<b>12.642</b>	<b>7.433</b>	<b>12.642</b>	<b>7.433</b>	<b>13.545</b>

The group furthermore has 9.8 mEUR overdraft facilities not utilized at period-end (partly Jyske Bank and partly Raiffeisen Bank, Russia) and own 12.7 mEUR Idavang Bonds.

Financial position kEUR 30.09.2022	RU	LT/DK	Group
Cash	6.080	6.563	12.643
Bond outstanding		-73.374	-73.374
Bond own		12.704	12.704
Bond prepaid cost		761	761
Russian debt/IFRS 16 Russia	-21.030		-21.030
Other debt/Leasing IFRS16 Lithuania		-2.747	-2.747
<b>Total</b>	<b>-14.950</b>	<b>-56.094</b>	<b>-71.044</b>
Available overdraft Jyske Bank			8.900
Available overdraft Russia			854

## Statement of changes in equity

EUR '000	Share capital	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2022	800	- 34.840	4.273	69.511	39.744
Profit/Loss for the period				13.049	13.049
Other comprehensive income		28.220	2.826		31.046
Total comprehensive income	-	28.220	2.826	13.049	44.095
Equity at 30th September 2022	800	- 6.620	7.099	82.560	83.839

EUR '000	Share capital	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2021	800	- 38.577	547	67.098	29.868
Profit/Loss for the period				2.413	2.413
Other comprehensive income		3.737	3.726		7.463
Total comprehensive income	-	3.737	3.726	2.413	9.876
Dividend					-
Repurchase shares					
Equity at 31st December 2021	800	- 34.840	4.273	69.511	39.744

## Notes

### Note 1 Basis of preparation and changes to the Group's accounting policies

The interim condensed consolidated financial statements for the 3 months ended 31st September 2022 have been prepared in accordance with Idavang A/S' accounting policies as stated in the latest financial statements for the company and in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for interim financial reporting of listed companies.

The consolidated financial statements are presented in thousand EUR.

The Interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as at 31st Dec 2021.

The Group's accounting policies is unchanged compared with the Group's annual financial statements as at 31st Dec 2021.

### Note 2 Biological assets measured at fair value

The change in the value of biological assets for Q3 2022 is stated in the below table. The total change in fair value is included in revenue reported in the income statement.

EUR '000	Q3 2022	Q3 2021	9M 2022	9M 2021	2021
<b>Commercial herd primo</b>	23.689	25.493	14.889	17.116	17.116
Change in fair value	2.609	-8.966	10.355	-662	-2.772
Exchange adjustments	3.583	617	4.637	690	545
<b>Commercial herd ultimo</b>	<b>29.881</b>	<b>17.144</b>	<b>29.881</b>	<b>17.144</b>	<b>14.889</b>
<b>Breeding herd primo</b>	13.069	14.554	12.094	15.469	15.469
Change in fair value	1.428	-2.524	3.954	-3.742	-3.780
Exchange adjustments	-2.040	-7	-3.591	296	405
<b>Breeding herd ultimo</b>	<b>12.456</b>	<b>12.023</b>	<b>12.456</b>	<b>12.023</b>	<b>12.094</b>
<b>Herd total primo</b>	36.758	40.048	26.982	32.585	32.585
Change in fair value due to volume	810	-6.591	8.719	-6.800	-6.824
Change in fair value due to price	3.227	-4.899	5.590	2.397	271
Exchange adjustments	1.542	610	1.046	986	950
<b>Herd total ultimo</b>	<b>42.337</b>	<b>29.168</b>	<b>42.337</b>	<b>29.168</b>	<b>26.982</b>
<b>Crop primo</b>	4.412	3.053	1.004	1.099	1.099
Change in fair value due to volume	-3.121	-2.336	-441	-309	-175
Change in fair value due to price	-	-	-	-	-
Exchange adjustments	-209	-84	519	-155	80
<b>Crop ultimo</b>	<b>1.083</b>	<b>634</b>	<b>1.083</b>	<b>634</b>	<b>1.004</b>
<b>Total Biological Assets primo</b>	41.170	43.101	27.986	33.684	33.684
Change in fair value due to volume	-2.311	-8.927	8.278	-7.110	-6.999
Change in fair value due to price	3.227	-4.899	5.590	2.397	271
Exchange adjustments	1.334	526	1.565	831	1.030
<b>Total Biological Assets ultimo</b>	<b>43.420</b>	<b>29.801</b>	<b>43.420</b>	<b>29.802</b>	<b>27.986</b>

### Note 3 Segment reporting

The group's results break down as follows on segments:

Q3 2022				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	20.213	11.960	-	32.172
Value adjustment, biological assets	2.720	507	-	3.227
Production costs	- 17.743	- 8.229	-	- 25.972
Administrative costs	- 516	- 426	- 128	- 1.070
Other income	3.110	64	-	3.173
Other expense	8	-	- 7	1
<b>Operating profit</b>	<b>7.792</b>	<b>3.875</b>	<b>- 135</b>	<b>11.532</b>
Net Financials	- 257	- 349	214	- 392
Foreign exchange adjustments	-	8	- 59	- 67
<b>Profit before tax</b>	<b>7.535</b>	<b>3.519</b>	<b>20</b>	<b>11.073</b>
Tax on profit for the year	- 1.140	- 29	-	- 1.169
<b>Profit for the period</b>	<b>6.395</b>	<b>3.490</b>	<b>20</b>	<b>9.905</b>
EUR '000				
Depreciations included in production cc-	633	- 1.526	-	- 2.159
<b>EBITDA</b>	<b>8.424</b>	<b>5.401</b>	<b>- 135</b>	<b>13.690</b>
<i>EBITDA fixed herd prices</i>	<i>5.704</i>	<i>4.894</i>	<i>- 135</i>	<i>10.463</i>
Q3 2021				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	13.728	12.975	-	26.703
Value adjustment, biological assets	- 4.359	- 540	-	- 4.899
Production costs	- 14.820	- 6.405	-	- 21.225
Administrative costs	- 425	- 377	- 98	- 901
Other income	1.129	492	-	1.621
Other expense	11	- 518	- 7	- 514
<b>Operating profit</b>	<b>- 4.736</b>	<b>5.627</b>	<b>- 105</b>	<b>786</b>
Net Financials	- 292	- 399	- 973	- 1.664
Foreign exchange adjustments	-	18	107	125
<b>Profit before tax</b>	<b>- 5.028</b>	<b>5.247</b>	<b>- 972</b>	<b>- 753</b>
Tax on profit for the year	745	- 38	-	707
<b>Profit for the period</b>	<b>- 4.284</b>	<b>5.209</b>	<b>- 972</b>	<b>- 46</b>
EUR '000				
Depreciations included in production cc-	714	- 1.138	-	- 1.851
<b>EBITDA</b>	<b>- 4.023</b>	<b>6.765</b>	<b>- 105</b>	<b>2.637</b>
<i>EBITDA fixed herd prices</i>	<i>337</i>	<i>7.305</i>	<i>- 105</i>	<i>7.536</i>

9M 2022				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	52.705	27.646	-	80.351
Value adjustment, biological assets	6.970	- 1.380	-	5.590
Production costs	- 48.549	- 24.896	-	- 73.445
Administrative costs	- 1.567	- 995	- 365	- 2.926
Other income	6.578	345	-	6.923
Other expense	20	-	- 7	13
<b>Operating profit</b>	<b>16.157</b>	<b>721</b>	<b>- 372</b>	<b>16.506</b>
Net Financials	- 815	- 857	- 607	- 2.280
Foreign exchange adjustments	-	113	1.086	1.199
<b>Profit before tax</b>	<b>15.341</b>	<b>- 23</b>	<b>107</b>	<b>15.425</b>
Tax on profit for the year	- 2.318	- 58	-	- 2.376
<b>Profit for the period</b>	<b>13.023</b>	<b>- 81</b>	<b>107</b>	<b>13.049</b>
EUR '000				
Depreciations included in production cost	- 1.946	- 3.661	-	- 5.607
<b>EBITDA</b>	<b>18.103</b>	<b>4.382</b>	<b>- 372</b>	<b>22.113</b>
<i>EBITDA fixed herd prices</i>	<i>11.133</i>	<i>5.762</i>	<i>- 372</i>	<i>16.523</i>
9M 2021				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	42.180	37.588	-	79.769
Value adjustment, biological assets	710	1.686	-	2.397
Production costs	- 42.050	- 27.433	-	- 69.483
Administrative costs	- 1.317	- 963	- 367	- 2.646
Other income	1.770	726	-	2.497
Other expense	333	- 518	- 7	- 192
<b>Operating profit</b>	<b>1.627</b>	<b>11.087</b>	<b>- 374</b>	<b>12.340</b>
Net Financials	- 897	- 1.061	- 2.891	- 4.848
Foreign exchange adjustments	-	15	607	591
<b>Profit before tax</b>	<b>731</b>	<b>10.011</b>	<b>- 2.658</b>	<b>8.084</b>
Tax on profit for the year	- 123	- 62	-	- 185
<b>Profit for the period</b>	<b>608</b>	<b>9.949</b>	<b>- 2.658</b>	<b>7.899</b>
EUR '000				
Depreciations included in production cost	- 2.196	- 3.257	-	- 5.454
<b>EBITDA</b>	<b>3.824</b>	<b>14.345</b>	<b>- 374</b>	<b>17.794</b>
<i>EBITDA fixed herd prices</i>	<i>3.113</i>	<i>12.658</i>	<i>- 374</i>	<i>15.398</i>



2021				
EUR '000	Lithuania	Russia	Other / Eliminations	Group
Revenue	53.864	46.298	-	100.163
Value adjustment, biological assets	159	112	-	271
Production costs	- 56.338	- 42.010	-	- 98.348
Administrative costs	- 1.808	- 1.287	- 626	- 3.721
Other income	2.818	6.865	-	9.683
Other expense	-	- 551	-	- 551
<b>Operating profit</b>	<b>- 1.305</b>	<b>9.428</b>	<b>- 626</b>	<b>7.497</b>
Net Financials	- 969	- 1.203	- 3.819	- 5.991
Foreign exchange adjustments	14	- 209	718	522
<b>Profit before tax</b>	<b>- 2.260</b>	<b>8.016</b>	<b>- 3.728</b>	<b>2.029</b>
Tax on profit for the year	492	- 107	-	385
<b>Profit for the period</b>	<b>- 1.768</b>	<b>7.909</b>	<b>- 3.728</b>	<b>2.413</b>
EUR '000				
Depreciations included in production cost	- 2.905	- 4.227	-	- 7.132
<b>EBITDA</b>	<b>1.600</b>	<b>13.655</b>	<b>- 626</b>	<b>14.629</b>
<i>EBITDA fixed herd prices</i>	<i>1.441</i>	<i>13.544</i>	<i>- 626</i>	<i>14.358</i>

#### Note 4 Summary of bond terms

<b>Issuer</b>	Idavang A/S
<b>Security package:</b>	(i) share pledges over Guarantors and Russian operating companies, (ii) mortgages over substantially Lithuanian real estate, (iii) Danish registered negative pledges, (iv) account pledge over IFC Deposit account and (v) assignment over intra-group loan (RUB 0.5bn - reduced from 0.9b RUB) from the
<b>Original Guarantors:</b>	Rus Invest Aps, Rurik A/S, Pskov Invest Aps, Idavang Russia A/S, UAB Idavang
<b>Status of the bond:</b>	Senior secured
<b>Currency:</b>	EUR
<b>Initial debt amount:</b>	EUR 75 millions
<b>Other facilities:</b>	Super senior RCF up to 9 mEUR, governed under an inter-
<b>Tenor</b>	5 years
<b>Pricing:</b>	3m EURIBOR + 725 bps p.a., quarterly interest payments, EURIBOR floor of 0.0%
<b>Rating:</b>	Unrated
<b>Call options:</b>	Non call during the first 30 months, then 50/33/25/10/0 after 30/36/42/48/57 Cash sweep of 50% of Free cash flow at 102.3925, starting from 2021
<b>Incurrence test</b>	NIBD/EBITDA LTM fixed herd price (net leverage) of 3.00 and
<b>Restricted payments</b>	No financial support (by way of loans, capital or similar) by the Issuer to Russian subsidiaries, except if funded by the super senior facility or if the incurrence test is met (excluding the IFC Deposit from Net Interest Bearing Debt)
<b>Information covenants:</b>	Annual audited statements, quarterly unaudited reports
<b>Change of control:</b>	Investor put at 101%
<b>Listing of bonds:</b>	Nasdaq Copenhagen
<b>Trustee:</b>	Nordic Trustee
<b>Governing law:</b>	Danish law

## Quarterly Financial Highlights and Key Ratios

EUR '000	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q4 2021	Q3 2021
<b>Income statement</b>						
Revenue	32.172	27.608	20.571	20.394	20.394	26.703
EBITDA	13.690	974	7.448	- 3.165	- 3.165	2.637
EBITDA fixed herd price	10.463	5.797	263	- 1.039	- 1.039	7.536
EBIT	11.532	- 773	5.747	- 4.843	- 4.843	786
Financial items, net	- 458	1.000	- 1.622	- 1.212	- 1.212	- 1.539
Profit/(loss) for the period	9.905	- 363	3.507	- 5.486	- 5.486	- 46
<b>Cash flow</b>						
Operating activity	8.005	9.850	- 3.171	6.023	6.023	- 323
Investing activity	- 3.831	1.223	- 2.155	- 804	- 804	1.298
Financing activity	- 2.236	- 8.909	- 2.197	889	889	- 5.611
Free cash flow	7.363	11.287	- 3.652	6.130	6.130	2.640
<b>Balance sheet</b>						
Non-current assets	113.257	117.465	89.582	93.926	93.926	94.257
Net working capital	45.715	40.892	36.149	26.866	26.866	36.684
Net operating assets	158.972	158.357	125.732	120.792	120.792	130.941
Total assets	187.100	182.814	143.444	146.166	146.166	149.962
Equity	83.839	75.975	39.963	39.744	39.744	44.658
Net interest bearing debt	71.045	78.657	82.475	78.455	78.455	83.099
<b>Key financials Group</b>						
EBITDA margin	42,6%	3,5%	36,2%	-15,5%	-15,5%	9,9%
EBITDA margin - fixed herd prices	32,5%	21,0%	1,3%	-5,1%	-5,1%	28,2%
Cash conversion	70,4%	194,7%	-1388,9%	-589,8%	-589,8%	35,0%
NIBD / EBITDA fixed price LTM	4,6	6,3	6,4	5,5	5,5	5,2
Equity ratio	44,8%	41,6%	27,9%	27,2%	27,2%	29,8%

## Appendix / Production information

### Idavang Group

	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
<b>Number of Sows average</b>					
Lithuania	15.196	15.204	15.296	15.247	15.104
Russia	10.161	9.215	7.830	6.993	9.124
Total	25.357	24.419	23.126	22.240	24.228
<b>Pigs sold (slaughterpigs, Weaners and Sows)</b>					
Lithuania	117.409	121.517	118.165	123.861	119.534
Russia	57.475	52.284	53.960	57.190	80.074
Total	174.884	173.801	172.125	181.051	199.608
<b>Displacement</b>					
Lithuania	1.779	- 2.308	2.952	- 8.269	710
Russia	16.603	12.694	894	- 677	- 2.832
Total	18.382	10.386	3.846	- 8.946	- 2.122
Russia, Ostrov					
<b>Total production</b>					
Lithuania	119.188	119.209	121.117	115.592	120.244
Russia	74.078	64.978	54.854	56.513	77.242
Total	193.266	184.187	175.971	172.105	197.486
<b>Feed cost kEUR</b>					
Lithuania	- 12.067	- 11.420	- 9.375	- 9.487	- 10.136
Russia	- 8.548	- 6.676	- 4.742	- 5.686	- 6.911
Total	- 20.615	- 18.096	- 14.117	- 15.174	- 17.048
<b>Feed conversion kg/kg</b>					
Lithuania	2,79	2,78	2,86	2,86	2,88
Russia	2,95	2,86	2,84	2,90	2,89
Group	2,85	2,81	2,85	2,87	2,89